Background: Proteolytic fragments of fibronectin have catabolic effects on cartilage and menisci. Platelet-rich plasma (PRP) is increasingly being used to treat a range of joint conditions, but it is unknown whether PRP influences fibronectin fragment (FN-f) procatabolic activity.
Fibronectin (FN) is a multidomain glycoprotein present in most extracellular matrices (ECMs), including cartilage 8 and synovium, 27 as a dimeric glycoprotein. The dimeric glycoprotein is formed through a pair of anti-parallel disulfide bonds at the C terminus linking single glycoproteins with a molecular weight of 230 to 270 kDa. 40 FN isoforms in adult cartilage are significantly different from fibronectins in other tissues and include predominantly the cartilagespecific (V 1 C) isoform (50%-80%) with smaller amounts of the of ED-B (1) isoform. 9 Intact FN has important roles in matrix assembly, morphogenesis, cell migration, and inflammation through the binding of multiple domains to itself and a range of matrix proteins and cell surface receptors, including collagen, fibulin-1, syndecan, and integrins. 35 a5b1 integrin is the major FN receptor expressed by articular chondrocytes and has important roles in regulating chondrocyte responses to mechanical loading. 33, 45, 58 FN levels are elevated in cartilage in osteoarthritis (OA) as a result of increased production and retention. 59 This increase of FN in OA cartilage is associated with an increase in FN levels in synovial fluid. 48 As well as being increased in amount, the FN in OA cartilage and synovium is fragmented, comprising FN-fragments (FN-f) of 30 to 200 kDa. 22 Unlike intact FN, these FN-f have catabolic activity. 21 FN-f bind to and penetrate cartilage tissue, resulting in proteinase expression and cartilage damage. 60 FN-f show potent catabolic activity in increasing expression of Toll-like receptors and inflammatory cytokines, including tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-1a; elevating production of matrix metalloproteinase (MMP) proteases; and suppressing proteoglycan synthesis. 13, 19, 20, 49, 51 FN-f are also released from articular cartilage after impact injury 7 and have been shown to increase production of MMPs by normal and OA meniscocytes in vitro, 50 indicating that a general increase in levels of these biologically active fragments in synovial fluid in OA or other joint disorders is also detrimental to meniscus structure and function.
Removal of FN-f from OA synovial fluid has been shown to diminish detrimental effects on cartilage, 22 indicating that targeting these molecules may be of benefit in attenuating the development or progression of cartilage and meniscal damage. A specific pharmacological agent that inhibits the catabolic effects of FN-f has not yet been developed, but there is increasing interest in the use of biological therapies such as hyaluronan (HA) and platelet-rich plasma (PRP) for the treatment of osteoarthritis and a range of other joint and musculoskeletal conditions. 15, 28, 29, 31, 38 PRP is a key source of molecules involved in tissue repair and regeneration and can deliver a variety of bioactive molecules. These include a number of growth factors recognized to be important in regulation of chondrocyte proliferation and anabolic function, including plateletderived growth factor, transforming growth factor b, fibroblast growth factor, and insulin-like growth factor 1. 5, 56 Delivery of a cocktail of agents, as is present in PRP, would be expected to be beneficial for repair of cartilage and meniscal injury and to enhance tissue repair by stimulation of anabolic activity while proinflammatory and catabolic pathways would be inhibited. 2, 26, 53 The aim of this study was to assess whether PRP has inhibitory effects on expression of proinflammatory and proteolytic molecules induced by FN-f in human meniscocytes and articular chondrocytes.
METHODS

Human Articular Chondrocyte and Meniscocyte Isolation and Culture
Human cartilage and meniscus samples were obtained from surgical discard tissue, with consent (TMU-JIRB No.201305003), at knee joint arthroplasty from patients with OA (n = 43; mean age 72.86 years; range, 56-84 years). Residual OA cartilage with predominantly grade II and III lesions (Collins/McElligot system) from each joint was removed and pooled. Cartilage and meniscus tissues were cut into small fragments; incubated with antimicrobial solution containing 500 IU/mL penicillin (Gibco; Invitrogen), 500 mg/mL streptomycin (Gibco), and 2.5 mg/mL Fungizone (Sigma) for 4 hours; and then washed with sterile phosphate-buffered saline (PBS) before digestion. Cells were extracted by sequential enzymatic digestion with 0.25% trypsin (Gibco) and collagenase type H (Sigma). Extracted cells were resuspended in 10 mL of Dulbecco's modified Eagle's medium/Nutrient Mixture F-12 HAM medium (Gibco) supplemented with 10% FBS (Gibco), 100 IU/mL penicillin, and 100 mg/mL streptomycin; seeded in complete medium at a density of 5 3 10 5 cell/mL in 60-mm Petri dishes (TPP); and cultured in a humidified 5% CO 2 incubator at 37°C for further experimental procedures. Cells between passages 3 and 5 were used.
Experimental Protocol
Human articular chondrocytes and meniscocytes were seeded at 5 3 10 5 cells/dish and grown as a monolayer for 5 days in 60-mm tissue culture Petri dishes. Cells were washed with sterile PBS twice, placed in serum-free media for 2 hours, and then co-incubated with fibronectin proteolytic fragments 30 kDa at a concentration of 0.5 mg/mL for 24 hours. Freeze-dried powder of PRP was prepared by Regen Lab and Regenkit (Regen Lab) by centrifugation of peripheral blood, using a thixotropic gel for cell separation and citrate as anticoagulant. The obtained PRP was approximately 3.3-fold platelet increase above baseline. Each ampoule of PRP was dissolved with 1 mL of distilled water. The concentrations of 2 major growth factors were as follows: transforming growth factor-beta1 (TGF-b1) 125.9 pg/mL and platelet-derived growth factor (PDGF) 40.8 pg/mL. Then 80 mL of PRP solution was added to cells with 2 mL of medium to yield final concentrations of TGF-b1 5.036 pg/mL and PDGF 1.632 pg/mL.
Extraction of RNA and Real-Time Polymerase Chain Reaction
Total RNA was extracted using TRIzol RNA Isolation Reagents (Invitrogen). For first-strand complementary DNA (cDNA) synthesis, 2 mg of total RNA was used in a single-round reverse-transcription reaction by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative polymerase chain reactions were carried out in a final volume of 20 mL containing 1 mL of 20X TaqMan Gene Expression Assay probe (Applied Biosystems), 10 mL of 2X TaqMan Gene Expression Master Mix, 5 mL of RNase-free water, and 4 mL of cDNA. Complement DNAs were amplified with the following condition: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 60 seconds, by use of a ViiA7 real-time polymerase chain reaction system (Applied Biosystems). Resultant cycle threshold (Ct) values were normalized to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and analyzed using the 2 -DDCt method. The TaqMan Probes used for gene expression studies are listed in Table 1 .
Microarray Assay and Data Analysis
RNA was extracted from control, and cells were incubated with 30-kDa FN-f. Then, 0.2 mg of total RNA was amplified by a Low Input Quick-Amp Labeling kit (Agilent Technologies) and labeled with Cy3 (Agilent Technologies); 0.6 mg of Cy3-labled cRNA was fragmented to an average size of 50 to 100 nucleotides by incubation with fragmentation buffer at 60°C for 30 minutes. Correspondingly fragmented labeled cRNA was then pooled and hybridized to Agilent SurePrint G3 Human V2 GE 8360K Microarray (Agilent Technologies) at 65°C for 17 hours. After washing and drying by nitrogen gun blowing, microarrays were scanned with an Agilent microarray scanner at 535 nm. Scanned images were analyzed by Feature extraction 10.5.1.1 software (Agilent Technologies). The microarray data comply with MIAME (Minimum Information About a Microarray Experiment) guidelines, and the raw data have been deposited in a MIAME-compliant database.
Protein Extraction and Western Blotting
After stimulation, cells were immediately washed with icecold PBS and protein was extracted with standard lysis buffer at 4°C for 15 minutes. Whole-cell lysates were collected after centrifugation at 13,000 rpm for 10 minutes. Equal amounts of protein were loaded onto 10% sodium dodecyl sulfate-polyacrylamide gel and after electrophoresis were transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Membranes were blocked overnight at 4°C with 2% bovine serum albumin in Tris-buffered saline with Tween 20 (TBST; 12.5 mM Tris/HCl, pH 7.6, 137 mM NaCl, 0.1% Tween 20). After washing with TBST, blots were incubated at 4°C overnight with primary antibodies (PathScan Multiplex Western Cocktail I 1/1000; p44/42 MAPK 1/1000; AKT 1/1000) (all from Cell Signaling Technology) diluted in TBST, and washed 6 times before incubation with horseradish peroxidase (HRP)-labeled secondary antibody 1/5000 (DakoCytomation) for 1 hour at room temperature. Membranes were rewashed extensively, and antibody binding was visualized with Immobilon Western HRP Substrate (Millipore). Immunoblots were scanned by a UVP BioSpectrum AC image system (UVP) and quantitated using VisionWork LS software (UVP). Anti-alpha-tubulin (1/5000; Abcam) acted as internal control.
Enzyme-Linked Immunosorbent Assay
Quantification of IL-8 (CXCL8) in supernatants of cultured medium was carried out using Quantikine enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems).
Statistical Analysis
The values were expressed as fold of band intensity of the target gene or protein to the internal control GAPDH gene or alpha-tubulin. The results are expressed as mean 6 SD. Data were analyzed by use of SPSS statistical software 18.0 (IBM Corp); all statistical tests used the Student t test, and P \ .05 was considered statistically significant.
RESULTS
PRP Attenuates FN-f-Induced Chemokine Gene Expression in Meniscocytes and Articular Chondrocytes
Microarray Analysis. To investigate the global gene change in meniscocytes as a result of stimulation with 0.5 mg/mL 30-kDa FN-f, an initial microarray assay was carried out. Analysis with the GeneSpring GX software showed that expression of 258 genes was significantly altered. Novel findings were the upregulation of several chemokine genes. The top 5 upregulated genes were IL-8 (CXCL8), CCL20, IL-6, CXCL10, and CCL5, respectively ( Table 2 ). To assess whether PRP had any effect on the 30-kDa FN-f-induced changes in gene expression, meniscocytes were co-incubated with PRP and 30-kDa FN-f. With coincubation there was a significant downregulation of expression of each of these top 5 upregulated genes rather than the increased expression seen with FN-f treatment alone ( Table 2) .
Quantitative Gene Expression. To confirm these results and to establish whether similar effects were seen in articular chondrocytes, experiments were undertaken in which changes in gene expression were assessed by quantitative 
Vol. 43 Figure  2A ). This enhanced production was significantly suppressed by PRP coincubation (266.38 6 214.09 pg/mL, P = .0087) (Figure 2A Figure 2B ). There was a small but nonsignificant increase in IL-8 levels when articular chondrocytes were incubated with PRP alone (237. 14 Figure 3A) . Articular chondrocyte expression of MMP1, MMP3, and MMP13 genes was significantly upregulated by incubation with 30-kDa FN-f (17.6 6 11.3-fold, 29.2 6 18.3-fold, and 6.3 6 5.7-fold, respectively). This effect was significantly attenuated by cotreatment with PRP (3.4 6 1.9-fold, 4.3 6 3.1-fold, and 2.4 6 0.6-fold, respectively). In contrast to meniscocytes, MMP2 and MMP9 gene expression was not upregulated by 30-kDa FN-f stimulation. MMP1, MMP2, MMP3, MMP9, and MMP13 showed no significant gene regulation after PRP treatment alone ( Figure 3B ).
Akt and p44/42 MAP Kinase Phosphorylation Induced by PRP
To investigate potential mechanisms by which PRP may influence chemokine and MMP gene expression, we looked at the activation of Akt and p44/42 mitogen-activated protein (MAP) kinase, both molecules being recognized as important regulatory intracellular signaling pathways in chondrocytes and meniscocytes. After stimulation with PRP, Akt phosphorylation was rapidly increased in meniscocytes and maintained for up to 3 hours (16.63 6 5.28fold, P = .0096, at 0.5 h; 10.47 6 1.94-fold, P = .0023, at 1 h; 4.74 6 2.42-fold, P = .0533, at 3 h; compared with baseline). The p44/42 phosphorylation was similarly increased over the same time course (5.24 6 1.23-fold, P = .0015, at 0.5 h; 3.66 6 0.95-fold, P = .0033, at 1 h; 4.54 6 2.29fold, P = .0258, at 3 h; compared with baseline). Under identical conditions, similar results were seen when articular 
DISCUSSION
In this study, we aimed to assess the influence of PRP on FN-f-induced proinflammatory and proteolytic activity of human meniscocytes and articular chondrocytes. Using a gene microarray, we found that 30-kDa FN-f induces increased gene expression of several chemokines in meniscocytes and chondrocytes. In addition to confirming observations that FN-f increases expression of MMP1, MMP2, MMP3, MMP13, IL-6, and IL-8 in meniscocytes, 50 we have, for the first time, identified that FN-f also increases expression of MMP9 and CCL5, CCL20, and CXCL10 chemokines in human meniscocytes. Similar effects are evident in articular chondrocytes, although we found no change in MMP2 or MMP9 expression in these cells, consistent with findings by others. 49 Importantly, costimulation of both meniscocytes and articular chondrocytes with PRP significantly attenuated the FN-f increased expression of chemokines and MMPs. Currently, 44 human chemokine ligands and 21 chemokine receptors have been described. Chemokine receptors contain 7 transmembrane domains and are G proteincoupled. 42 While chemokines act as critical extracellular mediators of cell migration, particularly in the immune system, 34 there is increasing interest in potential roles as inflammatory mediators in joint tissues. Chondrocytes and meniscocytes express numerous CC and CXC chemokines, including CCL2 (MCP-1), CCL3 (MIP-1a), CCL11 (eotaxin-1), CXCL1, CXCL2, CXCL3, and IL-8 (CXCL8), in addition to a number of chemokine receptors that potentially play important roles in activating catabolic pathways. 23, 47, 50 The pattern of chemokine and chemokine Vol. 43, No. 10, 2015 PRP Attenuates FN-f-Induced Chemokine and MMP Expression 2485 receptor expression in normal and OA chondrocytes suggests that chemokines have an effect in cartilage homeostasis and release of matrix-degrading enzymes in normal cartilage remodeling and cartilage breakdown. 11 Chemokine levels are increased in synovial fluid in patients with osteoarthritis. 18 Chemokine and chemokine receptor expression is also elevated in damaged menisci, 6 indicating that chemokine production in cartilage or meniscus due to biomechanical injury is important in the development of degenerative joint disease. 7 Our observation that meniscocytes, in addition to chondrocytes, express CCL5, CCL20, and CXCL10 chemokines and that expression of these cytokines is increased in articular chondrocytes and meniscocytes on exposure to the proinflammatory 30-kDa FN-f is novel. The effect of increased expression of these chemokines in cartilage and menisci is not yet clear. While IL-1b and high-mobility group protein 1 (HMGB1) increase expression of CCL5, CCL20, and CXCL10 chemokines in human chondrocytes, expression of CCL5 is decreased by the chondroprotective cytokine IL-4, indicating likely roles as proinflammatory mediators in the OA. 1, 3, 39 Cartilage breakdown results in production of metabolically active breakdown products such as FN-f. It is likely, although not yet confirmed, that FN-f can also be produced in menisci after acute or chronic degeneration and can affect all intra-articular tissues. Meniscocytes express a range of MMPs, including MMP1, MMP2, MMP3, MMP8, MMP9, and MMP13. 32 Levels of MMPs in synovial fluid are elevated rapidly in patients with a meniscal injury and remain elevated for at least 20 years after injury. 30 Targeting MMP activity within the joint may prevent long-term damage. Procatabolic FN-f appear to act predominantly through the a5b1 integrin receptor. 57 Thus, it would be possible to attempt to influence FN-f activity through targeting this receptor. However, because single agent therapies are increasingly found to be ineffective, there is interest in more broad-based biological approaches to treating joint injury and osteoarthritis, especially in their early phases. Targeting pathways activated by FN-f may be an effective means of inhibiting production of multiple mediators of cartilage destruction. 43 Autologous PRP injections were first used in 1987 in open heart surgery. 14 As a low-cost and minimally invasive way to obtain a natural concentration of autologous growth factors, PRP is being studied in different fields of medicine for its ability to aid tissue regeneration. 12, 16 PRP has been shown to enhance the healing of meniscal defects in a rabbit model. 24 Preclinical studies showing that PRP enhances chondrocyte viability, proliferation, and matrix production provide mechanistic support for the use of intra-articular PRP injection. 25, 36 The optimal concentration, composition, and relative importance of each of the components of PRP for clinical use remain unclear. Platelet concentrations of 2.5-to 3-fold above baseline are considered to be ideal, with higher concentrations potentially inhibiting tissue healing. 17, 46, 55 Furthermore, the ideal platelet concentration may depend on the target parameter (eg, direct promotion of tissue healing or stem cell recruitment), the tissue being treated (eg, bone, cartilage, or tendon), and stage of disease or wound healing. Consequently, the ideal platelet concentration for various clinical scenarios remains unknown. PRP concentration can vary considerably depending on an individual's blood platelet levels from day to day, diet, general health, medication, and exercise. The method of PRP preparation also influences platelet concentration and levels of growth factors. PRP used in treatment of osteoarthritis usually contains between 2-and 6-fold normal platelet concentrations, 41 although the optimal protocol for PRP injection in knee OA has not been defined. One study showed that PRP, approximately 6.8-fold above baseline, inhibited the inflammatory processes in human osteoarthritic chondrocytes, 53 whereas a double-blinded, randomized controlled trial using PRP with a platelet concentration of approximately 3-fold above baseline showed benefit over placebo. 37 Other randomized controlled trials have also shown that PRP injection, although with variable preparation formulas, provides symptomatic relief in early knee OA, 37 a significantly better clinical outcome compared with HA treatment in grade III gonarthrosis, 10 and efficacy in management of pain and inflammation in OA. 2, 26 The commercially available PRP preparation we used had a platelet concentration of 3.3-fold and is within the therapeutic range. The preparation contained 125.9 and 40.8 pg/mL of TGF-b1 and PDGF, respectively, which, at the final concentration used in our experimental model system, are levels at which these agents would be expected to be biologically active. 44 In the current study, the levels of Akt and p44/42 MAP kinase phosphorylation rapidly increased in both meniscocytes and articular chondrocytes upon incubation with PRP. This is in line with the published literature on Akt and p44/42 MAP kinase phosphorylation after incubation of chondrocytes with a range of growth factors and cytokines. 4 We have shown that PRP can attenuate the effects of FN-f on both chondrocyte and meniscocyte production of procatabolic chemokines and MMPs. The mechanisms by which these effects are produced are not clear but are likely to be multifactorial, as PRP can potentially affect numerous overlapping pathways simultaneously due to the presence of a number of anti-inflammatory cytokines and anabolic growth factors. 2 Interestingly PRP has been shown to stimulate endogenous HA production and show Vol. 43, No. 10, 2015 PRP Attenuates FN-f-Induced Chemokine and MMP Expression 2487 similar effects to HA in the suppression of inflammatory gene and protein expression in synoviocytes and cartilage. 52 High-molecular-weight (800 kDa) HA is believed to be effective in vitro and in vivo in blocking the catabolic action of FN-f by preventing entry of the fragments into the cartilage. 54 A recent in vitro study comparing the activity of HA and PRP on the expression of anabolic and catabolic genes and inflammatory mediators from human OA cartilage and synoviocytes indicated that while both agents decreased catabolic activity, PRP treatment also caused a significant reduction of MMP13, an increase in hyaluronan synthase-2 expression in synoviocytes, and an increase in cartilage synthetic activity compared with HA. 52 
CONCLUSION
In the current study, 30-kDa FN-f-induced production of a range of chemokines and MMPs, including IL-8, IL-6, CCL20, CCL5, CXCL10, MMP1, MMP3, and MMP13, by both meniscocytes and articular chondrocytes was attenuated by PRP treatment. These observations suggest the mechanism by which PRP might help osteoarthritis and suggest a rationale for continued limited clinical trials.
Variations in the composition of PRP from patient to patient are recognized, however, and composition may also vary depending on the device and protocols used for preparation and the methods and time of storage. Because of these limitations and questions remaining about potential interactions with other biologics or materials, the use of PRP in orthopaedics needs to be further studied.
